29 References Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med 2020;383(27):2652-2664. doi: 10.1056/NEJMra2002697. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017;389(10080):1741-1745. doi: 10.1016/S0140-6736(16)31711-1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017;389(10080):1756-1770. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol 2018;15(1):39-49. doi: 10.1038/nrgastro.2017.136. Franke A, McGovernDP, Barrett JC,Wang K, Radford-Smith GL, AhmadT, et al. Genome-widemeta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42(12):111825. doi: 10.1038/ng.717. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2017;14(12):739-749. doi: 10.1038/nrgastro.2017.110. Maaser C, SturmA, Vavricka SR, KucharzikT, FiorinoG, AnneseV, et al. ECCO-ESGARGuideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113. Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-Camps MJL, et al. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am J Gastroenterol 2017;112(2):325-336. doi: 10.1038/ajg.2016.524. Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol 2014;20(12):3231-44. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95. doi: 10.1067/mcp.2001.113989. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14(1):32-9. doi: 10.1002/ibd.20275. 12. Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer MM, et al. Fecal Calprotectin Measured by Patients at Home Using Smartphones–A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. InflammBowel Dis 2016;22(2):336-44. doi: 10.1097/MIB.0000000000000619. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101(10):2410-22. doi: 10.1111/j.15720241.2006.00840.x. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56(10):1394403. doi: 10.1136/gut.2006.108043. Torres J, Petralia F, SatoT, Wang P, Telesco SE, Choung RS, et al. SerumBiomarkers Identify PatientsWhoWill Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology 2020;159(1):96104. doi: 10.1053/j.gastro.2020.03.007. Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol 2016;22(3):1304-10. doi: 10.3748/wjg. v22.i3.1304. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 General introduction and outline of the thesis
RkJQdWJsaXNoZXIy MjY0ODMw